ST PETERSBURG, RUSSIA AUGUST 10, 2021: An ampoule with the Sputnik Light single-dose vaccine against the novel coronavirus at a COVID-19 vaccination site at the Galeria shopping mall, the biggest mobile vaccination clinic in St Petersburg with a capacity of up to a thousand people a day. Alexander Demianchuk/TASS Ðîññèÿ. Ñàíêò-Ïåòåðáóðã. Âàêöèíà “Ñïóòíèê Ëàéò” â ïóíêòå âàêöèíàöèè îò COVID-19 â ÒÐÖ “Ãàëåðåÿ” ó Ìîñêîâñêîãî âîêçàëà. Êðóïíåéøèé â ãîðîäå ïóíêò âàêöèíàöèè äëÿ ïðîôèëàêòèêè êîðîíàâèðóñíîé èíôåêöèè ðàññ÷èòàí íà ïðèåì äî òûñÿ÷è ÷åëîâåê â äåíü. Àëåêñàíäð Äåìüÿí÷óê/ÒÀÑÑ
According to Alexander Gintsburg, the nasal spray vaccine consists of the second component of the Sputnik V vaccine
MOSCOW, August 21. /TASS/. Researchers at Russia’s Gamaleya Center have completed pre-clinical trials of a nasal spray coronavirus vaccine and are ready to launch clinical trials, the center’s Director Alexander Gintsburg told TASS.
“There has been serious progress made in terms of the nasal spray vaccine, pre-clinical trials are over. We are ready to move on to clinical trials,” he said. According to Gintsburg, the nasal spray vaccine consists of the second component of the Sputnik V vaccine.
The Gamaleya Center’s director said earlier that clinical trials could begin in late 2021 or early 2022 and the vaccine was expected to be approved in 2022.